URO TODAY: New drugs – still being trialled – are proving effective treatment of prostate cancer bone metastases and prevention of fractures associated with androgen deprivation therapy. READ MORE>
Posts Tagged ‘zoledronic acid’
Single dose of bisphosphonate drug reduces bone loss after a year of hormone therapy
Posted in Bone loss, Hormone therapy, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged ADT-induced bone loss, advanced prostate cancer, androgen-deprivation therapy, Bone mineral density, bone mineral loss, cancer research, hormone-naive prostate carcinoma, Japan, Kanagawa, Kitasato University School of Medicine, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, zoledronic acid on July 12, 2009| Leave a Comment »
JULY 12: URO TODAY: Bone loss begins at 6 months with androgen deprivation therapy (ADT). A single infusion of zoledronic acid in patients receiving ADT reduces bone mineral loss and maintains bone mineral density (BMD) at least at 12 months during ADT. Further study is needed to determine the best dosing schedule to prevent ADT-induced bone loss in men with hormone-naive prostate carcinoma. READ MORE>
Prostablog 